Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $11.02 Analyst target: $9.17 Upside: -16.79%
Certara Inc. provides software products and technology services to clients for biosimulation in drug discovery, preclinical and clinical research, regulatory filings, and market access. The company is headquartered in Princeton, New Jersey.
See the full interactive analysis & chart →Informational only — not investment advice.